Home > Journals > Minerva Chirurgica > Past Issues > Articles online first > Minerva Chirurgica 2018 Feb 01

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA CHIRURGICA

A Journal on Surgery


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,115


eTOC

 

Minerva Chirurgica 2018 Feb 01

DOI: 10.23736/S0026-4733.18.07512-0

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Development of epidermal growth factor receptor targeted therapy in pancreatic cancer

Liu QING, Wang QING

China-Japan Union Hospital of Jilin University, Changchun, China


PDF  


The epidermal growth factor receptor (EGFR) family are a series of important cancer therapeutic targets involved in cancer biology. These genes play an important role in tumor biological characteristics including angiogenesis, cell survival, invasion and glucose metabolism. In recent years, progresses have been achieved upon the cellular and molecular biological characteristics of EGFR and its role in cancer development based on the study of tumor specimens and experimental animal model. EGFR(HER1/ErbB) is overexpressed in over sixty percent of triple-negative breast cancers and occurs in pancreatic, bladder, lung and head-and-neck cancers. Up to now, EGFR inhibitors have been applied in various of cancer, such as lung, breast, bladder and head and neck cancers etc., in which the combination of EGFR inhibitors plus chemotherapeutic agents is now seen as the standard of care for advanced/metastatic pancreatic cancer. For these reasons, EGFR inhibitors and their therapeutic effect for pancreatic cancer is becoming the focus in Laboratory and clinical research. In this paper, research progress of the development of epidermal growth factor receptor targeted therapy in pancreatic cancer is introduced.


KEY WORDS: EGFR - Molecular targeted therapy - Pancreatic cancer

top of page

Publication History

Article first published online: February 01, 2018
Manuscript accepted: January 31, 2018
Manuscript received: September 18, 2017

Cite this article as

Qing L, Qing W. Development of epidermal growth factor receptor targeted therapy in pancreatic cancer. Minerva Chir 2018 Feb 01. DOI: 10.23736/S0026-4733.18.07512-0

Corresponding author e-mail

wangqing_jlu@126.com